APEPTICO - Innovation in peptide drugs
SOLNATIDE: Read the most exciting news related to the exploration of safety, tolerability and clinical efficacy of SOLNATIDE IMP in patients infected with the 2019 new Coronavirus (SARS-CoV-2)
zurück
SOLNATIDE: Read the most exciting news related to the exploration of safety, tolerability and clinical efficacy of SOLNATIDE IMP in patients infected with the 2019 new Coronavirus (SARS-CoV-2)
zurück
APEPTICO Forschung und Entwicklung GmbH., c/o INITS, Rudolf Sallinger Platz 1, A-1030 Vienna, Austria
Tel: +43 (0)664 1432919, Fax: +43 (0)664 1477280, office@apeptico.com, www.apeptico.com